ArticleJournal of medical virology2021
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.
Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Cerebrospinal fluid cytokines in COVID-19: a review and meta-analysis.Journal of neurology · 2023Pooled it
- Serum IL-6, IL-1b, IL-8, and cerebrospinal fluid biochemical profiles in patients with lateral skull base temporal bone fractures and cerebrospinal fluid leak.Journal of medical biochemistry · 2025Article
- Hydroxychloroquine Mitigates Cytokine Storm and Prevents Critical Illness Neuromyopathy in a Rat Sepsis Model.Medicina (Kaunas, Lithuania) · 2024Article
- COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Anxiety in post-covid-19 syndrome - prevalence, mechanisms and treatment.Neuroscience applied · 2024Review
- Long-term, unilateral third cranial nerve palsy, ocular myositis, and high CSF interleukine-2 persisting for 14 months after mild SARS-CoV-2 infection-case report.Clinics (Sao Paulo, Brazil) · 2024Article
- Reconstructing the cytokine view for the multi-view prediction of COVID-19 mortality.BMC infectious diseases · 2023Article
- Susceptibility and severity of COVID-19 and risk of psychiatric disorders in European populations: a Mendelian randomization study.Frontiers in psychiatry · 2023Article
- How COVID-19 shaped mental health: from infection to pandemic effects.Nature medicine · 2022Review
- The challenge of diagnosing Guillain-Barre syndrome in patients with COVID-19 in the intensive care unit.Journal of neuroimmunology · 2022Article
- Peripheral Neuropathy in Patients Recovering from Severe COVID-19: A Case Series.Medicina (Kaunas, Lithuania) · 2022Article
- Occupational and Physical Therapy Strategies for the Rehabilitation of COVID-19-Related Guillain-Barré Syndrome in the Long-term Acute Care Hospital Setting: Case Report.JMIR rehabilitation and assistive technologies · 2022Article
- Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study.Journal of neurology · 2022Observational
- The impact of supervised physical exercise on chemokines and cytokines in recovered COVID-19 patients.Frontiers in immunology · 2022Article
- Guillain-Barré syndrome is immunogenic in SARS-CoV-2 infected.Journal of medical virology · 2022Article
- Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.Journal of medical virology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case series describes three patients affected by severe acute respiratory syndrome coronavirus 2, who developed polyradiculoneuritis as a probable neurological complication of coronavirus disease 2019 (COVID-19). A diagnosis of Guillain Barré syndrome was made on the basis of clinical symptoms, cerebrospinal fluid analysis, and electroneurography. In all of them, the therapeutic approach included the administration of intravenous immunoglobulin (0.4 gr/kg for 5 days), which resulted in the improvement of neurological symptoms. Clinical neurophysiology revealed the presence of conduction block, absence of F waves, and in two cases, a significant decrease in amplitude of compound motor action potential cMAP. Due to the potential role of inflammation on symptoms development and prognosis, interleukin-6 (IL-6) and IL-8 levels were measured in serum and cerebrospinal fluid during the acute phase, while only serum was tested after recovery. Both IL-6 and IL-8 were found increased during the acute phase, both in the serum and cerebrospinal fluid, whereas 4 months after admission (at complete recovery), only IL-8 remained elevated in the serum. These results confirm the inflammatory response that might be linked to peripheral nervous system complications and encourage the use of IL-6 and IL-8 as prognostic biomarkers in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.